Inhibrx Biosciences Inc
INBX
NASDAQ
Biotechnology
$88.37
USD
-8.64 (-8.91%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.37B
Volume 268.3K
Revenue
$1.30M
TTM
+550.0%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-130.19M
TTM
-107.6%
YoY
Operating Cash Flow
$-131.93M
TTM
+21.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 1.3 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | +1200.0% | — | -100.0% | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 1.3 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 6.0 | 6.4 | 5.3 | 5.6 | 5.7 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 42.9 | 28.7 | 33.8 | 30.9 | 30.9 |
Operating Income | -42.9 | -27.4 | -33.8 | -30.9 | -30.9 |
EBITDA | -42.2 | -26.7 | -33.2 | -30.4 | -30.4 |
Other Income / Expense | -0.1 | -0.2 | -0.0 | -0.0 | -0.0 |
Total Other Income / Expense | -0.4 | -1.3 | -1.4 | -1.9 | -2.5 |
Income Before Income Taxes | -43.3 | -28.7 | -35.3 | -32.8 | -33.4 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -43.3 | -28.7 | -35.3 | -32.8 | -33.4 |
Consolidated Net Income / Loss | -43.3 | -28.7 | -35.3 | -32.8 | -33.4 |
Net Income Attributable to Common Shareholders | -43.3 | -28.7 | -35.3 | -32.8 | -33.4 |
Basic EPS | -$2.80 | -$1.85 | -$2.28 | -$2.11 | -$2.15 |
Diluted EPS | -$2.80 | -$1.85 | -$2.28 | -$2.11 | -$2.15 |
Basic Shares Outstanding | 15.5M | 15.5M | 15.5M | 15.5M | 15.6M |
Diluted Shares Outstanding | 15.5M | 15.5M | 15.5M | 15.5M | 15.6M |